Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Software Development

14 Feb 2008 07:01

Angle PLC14 February 2008 For Immediate Release 14 February 2008 ANGLE plc Software Development Kit Launched by Geomerics ANGLE plc is pleased to announce that its venture company Geomerics hascompleted its Software Development Kit (SDK) for Enlighten, the revolutionaryradiosity lighting engine for PLAYSTATION(R)3, the Xbox 360(TM) entertainmentsystem from Microsoft and PC. Enlighten's SDK comprises a modular toolkit withan emphasis on easy integration into existing development frameworks. It alsoboasts intuitive operation designed with artists in mind and full support forindustry standard packages such as 3D Studio Max and Maya for maximumoperability. Enlighten's radiosity solution represents a generational step in videogamegraphics technology, surpassing all currently popular lighting techniques.Radiosity is the ability to model light as it bounces from surfaces and it iskey to generating high quality visual images. Current technologies forgenerating radiosity lighting involve either pre-computing it in advance, orfaking it with multiple hidden lights. These methods are typically inflexible,time-consuming and often generate poor results. Enlighten computes full multiple-bounce radiosity at runtime, giving developersthe quality of pre-computed lighting without the pre-compute. In-game lightingcan also be fully dynamic, giving designers a powerful new tool with hugepotential for enhancing the atmosphere and mood of any scene. Additionally,Enlighten's instantaneous feedback means that artists are freed up to experimentwith light, shadow and colour in dramatic new ways - just as if they were usingreal lights on a studio set. Gary Lewis, CEO, Geomerics comments: "We are delighted to be announcing the launch of the Enlighten SDK. With our SDKcompleted, we are looking forward to seeing Enlighten gaining the support itdeserves within the games industry. We are certain that once developers gettheir hands on the SDK and experiment with it for themselves, they will see thetrue power and versatility of Enlighten and the huge potential it has forrevolutionising the look of videogames for years to come." Geomerics will be at Expo Suite 561 throughout GDC Expo 2008, which runs from20th to the 22nd February. To book a meeting please contact: info@geomerics.com Enlighten is available for licensing for PC, Xbox 360 and Playstation 3. Formore information please contact: sales@geomerics.com Enquiries: ANGLE plc 01483 295830Andrew Newland, Chief ExecutiveIan Griffiths, Finance Director Buchanan Communications 0207 466 5000Richard Darby, Suzanne Brocks, James Strong Notes to Editors Angle plc Founded in 1994, ANGLE is an international venture management company focusingon the commercialisation of technology and the development of technology-basedindustry. ANGLE creates, develops and advises technology businesses on its ownbehalf and for its clients. ANGLE has a 48% equity holding in Geomerics Ltd.ANGLE is listed on AIM (AGL.L); further information can be found onwww.ANGLEplc.com Geomerics Ltd Geomerics is an innovation-led company specialising in graphics software for thegames industry and beyond. It is built on a combination of advanced in-house IP,a remarkable research team, and strong management experience. The company'sfirst product is Enlighten. Enlighten radically transforms the way that lightingis handled in computer games. Instead of pre-baking the effects of globalillumination into the scene they can now be computed at run time, allowing forfully dynamic lighting. This dramatically enhances realism as well as opening upa new world of creative possibilities for designers and artists. Further information can be found on www.geomerics.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
19th Jul 20137:00 amRNSNotification of Preliminary Results and Webcast
8th Jul 20137:00 amRNSParsortix Colorectal Cancer Validation
29th May 20137:00 amRNSDirector's Share Transfer
28th May 20137:00 amRNSParsortix Manufacturer Appointed
13th May 20137:00 amRNSPARSORTIX CELL HARVESTING
7th May 20137:00 amRNSParsortix Regulatory Approval Update
28th Feb 20137:00 amRNSParsortix Research Product Launch
15th Feb 201310:56 amRNSDirector's share transfer
31st Jan 20137:01 amRNSFundraising and Director's Dealings
31st Jan 20137:00 amRNSInterim Results
16th Jan 20137:00 amRNSNotification of Interim Results and Webcast
14th Jan 20137:00 amRNSParsortix Cell Recovery
7th Jan 20137:00 amRNSAppointment of NED
18th Dec 20127:00 amRNSParsortix Released to Research Partners
10th Dec 20127:00 amRNSBUSINESS UPDATE
18th Oct 20127:00 amRNSAppointment of Scientific Advisers
17th Oct 20123:45 pmRNSHolding(s) in the Company
11th Oct 20123:39 pmRNSResult of 2012 Annual General Meeting
3rd Sep 20127:00 amRNSIncreased Fundraising
1st Aug 20127:00 amRNSIncreased Fundraising
26th Jul 20127:01 amRNSFundraising
26th Jul 20127:00 amRNSPreliminary Results
24th Jul 20127:00 amRNSNotice of Preliminary Results and Conference Call
27th Jun 20127:00 amRNSOffer Unconditional for Novocellus' Partner Origio
7th Jun 20127:00 amRNSUpdate Re Novocellus' Partner ORIGIO A/S
16th May 20127:00 amRNSGeomerics Milestone Payment
30th Apr 20127:00 amRNSParsortix Design Breakthrough
26th Apr 20127:00 amRNSLaunches New Corporate Website
23rd Apr 20127:00 amRNSParsortix Update for Breast Cancer
17th Apr 20127:00 amRNSParsortix Validation for Ovarian Cancer
11th Apr 20127:00 amRNSNovocellus Embryosure® Trial Started
26th Mar 20127:00 amRNSGeomerics Update
15th Mar 20127:00 amRNSParsortix Validation for Colon Cancer
7th Mar 20128:00 amRNSHolding(s) in the Company
28th Feb 201212:00 pmRNSDirector Share Transfer
28th Feb 20128:00 amRNSTotal Voting Rights
27th Feb 20127:00 amRNSParsortix Research Partnership
22nd Feb 20127:00 amRNSSecond Novocellus Patent
26th Jan 20127:00 amRNSInterim Results
26th Jan 20127:00 amRNSNovocellus Update
26th Jan 20127:00 amRNSFundraising
23rd Jan 20127:01 amRNSParsortix Update
19th Jan 20127:00 amRNSNotice of Interim Results and Webcast
16th Dec 20117:00 amRNSParsortix Update - Validation for Lung Cancer
7th Dec 20117:00 amRNSParsortix Update
21st Nov 20117:00 amRNSShare Options
16th Nov 20117:00 amRNSNovocellus Update
15th Nov 20117:00 amRNSIssue of equity and Total Voting Rights
11th Nov 20117:00 amRNSValidation for Prostate Cancer
10th Nov 20117:00 amRNSChange of Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.